Compare Corning Incorporated (GLW) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Corning Incorporated trades at $135.06 (market cap $127.95B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Corning Incorporated is far larger — about 131.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Corning Incorporated pays a 0.75% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GLW | MRVI | |
|---|---|---|
Market Cap | $127.95B | $972.90M |
Volume | 7,325,250 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $255.79 | $9.00 |
52-Week Low | $78.03 | $2.83 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $134.83B | $1.08B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $140.91, down 4.31% today, amid a bearish technical outlook despite strong fundamentals. The stock shows robust earnings beats in recent quarters and recently secured a significant $3 billion fiber supply agreement with AT&T, positioning it well for AI-driven infrastructure demand. Analyst consensus remains bullish with a $171.25 price target, though technical indicators signal near-term weakness with support at $134.
GLW presents a compelling long-term investment opportunity driven by its leadership in optical communications and materials science, supported by strong revenue growth and improving profit margins. Key risks include ongoing patent litigation and market volatility, but institutional confidence remains high with 57% buy ratings and projected 2026 revenue growth to $17 billion.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
